

References

1. Stone, K. "Big Pharma's Merger Mania." About.com. <http://pharma.about.com/od/BigPharma/tp/Big-Pharmas-Merger-Mania.htm>.
2. Stovall, S. *Pharma Edges toward 'Patent Cliff'*; Wall Street Journal, June 15, 2011. <http://online.wsj.com/news/articles/SB10001424052702304186404576387073020214328>.
3. Paul, S. M.; Mytelka, D. S.; Dunwiddie, C. T.; Persinger, C. C.; Munos, B. H.; Lindborg, S. R.; Schacht, A. L. How to improve R&D productivity: the pharmaceutical industry's grand challenge. *Nat. Rev. Drug Discov.* **2010**, *9*, 203–214.
4. Ward, A. *High Cost of Hepatitis C Treatment Pills Is Hard to Swallow*; The Financial Times, June 27, 2014.
5. LaMattina, J. *Drug Truths: A Holiday Gift from Merck's Ken Frazier*; December 20, 2011. <http://johnlamattina.wordpress.com/2011/12/20/a-holiday-gift-from-mercks-ken-frazier/>.
6. Schumacher, C. *CRAMS Outsourcing in Pharmaceutical and Chemical Research and Manufacturing, Part II*. StepChange Innovations GmbH, Science and Technology Blog; 2012. <http://blog.stepchange-innovations.com/2012/08/crams-outsourcing-in-pharmaceutical-and-chemical-research-and-manufacturing-part-ii/#.VINxtslNcmQ>.
7. Getz, K.; Lamberti, M. J.; Mathias, A.; Stergiopoulos, S. Resizing the Global R&D Contract Service Market. *Contract Pharma* **2012**, *14*, 54.
8. Based on information posted in the Scynexis Inc. corporate website. <http://www.scynexis.com/pipeline/>.
9. *AMRI Announces Collaboration Agreement with Lilly for In-sourced Chemistry Services*; Albany Molecular Research Inc, November 7, 2011. http://www.amriglobal.com/news_and_publications/AMRI_Announces_Collaboration_Agreement_With_Lilly_for_In-sourced_Chemistry_Services_207_news.htm.
10. *Technology Transfer, Administration of the Bayh-dole Act by Research Universities*; U.S. Government Accounting Office (GAO), May 7, 1978. Report to Congressional Committees.
11. a. 35 U.S.C. 18 Patent Rights in Inventions Made with Federal Assistance.
b. 37 C.F.R. 401 – Rights to Inventions Made by Nonprofit Organizations and Small Business Firms under Grants, Contracts, and Cooperative Agreements.
12. Slusher, B. S.; Conn, P. J.; Frye, S.; Glicksman, M.; Arkin, M. Bringing together the academic drug discovery community. *Nat. Rev. Drug Discov.* **2013**, *12* (11), 811–812.
13. a. Ghosh, A. K.; Kincaid, J. F.; Cho, W.; Walters, D. E.; Krishnan, K.; Hussain, K. A.; Koo, Y.; Cho, H.; Rudall, C.; Holland, L.; Buthod, J. Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-[(hydroxyethyl)amino]sulfonamide isostere. *Bioorg. Med. Chem. Lett.* **1998**, *8* (6), 687–690.
b. Vazquez, M. L.; Mueller, R. A.; Talley, J. J.; Getman, D. P.; Decrescenzo, G. A.; Freskos, J. N.; Bertenshaw, D. E.; Heintz, R. M. *Hydroxyethylamino Sulfonamides Useful as Retroviral Protease Inhibitors*; 1995. WO 9506030 A1.
14. a. Schinazi, R. F.; McMillan, A.; Cannon, D.; Mathis, R.; Lloyd, R. M.; Peck, A.; Sommadossi, J. P.; St Clair, M.; Wilson, J.; Furman, P. A. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of Cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. *Antimicrob. Agents Chemother.* **1992**, *36* (11), 2423–2431.
b. Frick, L. W.; Lambe, C. U.; St John, L.; Taylor, L. C.; Nelson, D. J. Pharmacokinetics, Oral bioavailability, and metabolism in mice and cynomolgus monkeys of (2'R,5'S)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, an agent active against human immunodeficiency virus and human hepatitis B virus. *Antimicrob. Agents Chemother.* **1994**, *38* (12), 2722–2729.